What are the potential interactions between clindamycin and doxycycline with Truvada (emtricitabine/tenofovir disoproxil fumarate) and Isentress (raltegravir)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Drug Interactions Between Clindamycin/Doxycycline and Truvada/Isentress

Both clindamycin and doxycycline can be safely co-administered with Truvada (emtricitabine/tenofovir) and Isentress (raltegravir) without dose adjustments, as no clinically significant drug-drug interactions exist between these antibiotics and these antiretroviral agents. 1, 2

Doxycycline with Truvada and Isentress

  • Doxycycline has no significant interactions with integrase inhibitor-based regimens like Isentress (raltegravir) and can be safely co-administered without any dose modifications. 2

  • No clinically significant interactions occur between doxycycline and the nucleoside reverse transcriptase inhibitors in Truvada (emtricitabine and tenofovir disoproxil fumarate). 1

  • Raltegravir is not metabolized through CYP450 pathways and has minimal drug-drug interaction potential, making it compatible with most antibiotics including doxycycline. 1

  • The combination of raltegravir with tenofovir/emtricitabine has been extensively studied and shows no interactions with commonly used antibiotics. 3, 4

Clindamycin with Truvada and Isentress

  • Clindamycin has no documented interactions with either Truvada or Isentress based on their metabolic pathways and transporter profiles. 1

  • Tenofovir and emtricitabine are primarily renally excreted and do not undergo significant hepatic metabolism, eliminating potential interactions with clindamycin. 1

  • Raltegravir undergoes glucuronidation via UGT1A1 and is not affected by antibiotics like clindamycin that do not induce or inhibit this pathway. 1

Important Clinical Considerations

Antibiotics to Avoid with These Regimens

  • Rifamycin antibiotics (rifampin, rifabutin, rifapentine) are absolutely contraindicated with integrase inhibitor regimens as they significantly decrease drug concentrations and risk treatment failure. 2

  • If rifamycin-based tuberculosis treatment is required, switch to dolutegravir 50 mg twice daily with tenofovir/emtricitabine or use efavirenz-based regimens instead. 2

Monitoring Recommendations

  • Continue routine HIV viral load monitoring every 3-6 months to ensure maintained virologic suppression when any antibiotic is added. 5

  • Monitor renal function (creatinine clearance) at baseline and every 6 months while on Truvada, as tenofovir carries renal toxicity risk independent of antibiotic use. 6

  • No additional monitoring is required specifically for clindamycin or doxycycline interactions with these antiretrovirals. 1

Common Pitfalls to Avoid

  • Do not confuse the lack of interactions with clindamycin/doxycycline with the serious contraindications that exist for rifamycin antibiotics—these are entirely different drug classes. 2

  • Avoid zidovudine (AZT) if ribavirin is ever needed, as this combination increases anemia risk, though this is not relevant to clindamycin or doxycycline. 1

  • Ensure no gaps in antiretroviral coverage when treating infections—continue Truvada and Isentress without interruption while adding antibiotics. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Antibiotics Contraindicated with Biktarvy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

BIKTARVY and Doxycycline Co-administration Safety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Truvada Adverse Reactions and Monitoring

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.